Molecular Imaging

Molecular imaging (also called nuclear medicine or nuclear imaging) can image the function of cells inside the body at the molecular level. This includes the imaging modalities of positron emission computed tomography (PET) and single photon emission computed tomography (SPECT) imaging. How does PET and SPECT imaging work? Small amounts of radioactive material (radiopharmaceuticals) injected into a patient. These can use sugars or chemical traits to bond to specific cells. The radioactive material is taken up by cells that consume the sugars. The radiation emitted from inside the body is detected by photon detectors outside the body. Computers take the data to assemble images of the radiation emissions. Nuclear images may appear fuzzy or ghostly rather than the sharper resolution from MRI and CT.  But, it provides metabolic information at a cellular level, showing if there are defects in the function of the heart, areas of very high metabolic activity associated with cancer cells, or areas of inflammation, data not available from other modalities. These noninvasive imaging exams are used to diagnose cancer, heart disease, Alzheimer’s and Parkinson’s disease, bone disorders and other disorders. 

AAA financials show more than 28% spike in sales

A year-to-date sales report for the radiopharmaceutical company Advanced Accelerator Applications (AAA) indicates that the company experienced 28.9 percent growth in sales, equaling about $68.7 million in the first nine months of 2014. Net income for the first three quarters of the year was gauged at approximately $1.5 million.

Thumbnail

Capturing minute changes in DNA could aid early detection of breast cancer

Targeting oncogene-driven activation of DNA damage could be an effective way to tap into the earliest stages of cancer development, or tumorigenesis. An investigative molecular imaging agent was able to do just that in a preclinical Oxford University study published ahead of print Nov. 13 in the Journal of Nuclear Medicine.

Thumbnail

Lymphoseek gains EU approval for sentinel node mapping in select cancers

Navidea Biopharmaceuticals announced today that technetium-99m tilmanocept (Lymphoseek) has been approved by the European Commission for the detection of sentinel lymph node involvement in primary breast cancer, melanoma and localized squamous cell carcinoma.

Thumbnail

Protea’s gross revenues up 190% in third quarter

Protea Biosciences, a biomedical company based in Morgantown, W. Va, announced yesterday that third quarter financial results amounted to $517,569, the highest revenue on record for the company. However net losses are still steep at more than $4.6 million for the third quarter.

Thumbnail

Brain PET: Periodontal disease could be a culprit in amyloid burden

Even mild cases of dental disease could have long-term effects on amyloid plaque development and brain health, according to a neuroimaging study published online Nov. 5 in Neurobiology of Aging.

PSMA agents pinpoint prostate cancer throughout the body with SPECT, planar imaging

Two novel technetium-99m agents, when used with SPECT or planar imaging, have been found to effectively target prostate specific membrane antigen (PSMA) in advanced prostate cancer within bone, lymph nodes and soft tissues, according to a study published in the November issue of the Journal of Nuclear Medicine.

Thumbnail

FDG PET reigns for diagnosing infected prosthetic heart valves

Infections related to heart valve prosthesis are usually diagnosed with echocardiography, but it can miss key areas of infection. It is here that FDG PET or leukocute scintigraphy can step in, but a recent comparison study of the two nuclear medicine procedures published Nov. 13 in the Journal of Nuclear Medicine shows that FDG PET may be the best option.

Thumbnail

NorthStar snags additional $5.2M from NNSA for isotope technology

The U.S. Department of Energy’s National Nuclear Security Administration (NNSA) has agreed to provide supplemental funding for NorthStar Medical Radioisotopes’ medical isotope production venture.